胆道ステント市場：製品、エンドユーザー、用途、地域別、2026～2032年

胆道ステント市場の評価、2026～2032年

胆道狭窄や胆石などの胆道疾患の増加により、低侵襲治療の需要が大幅に増加しています。これらの治療に対する嗜好の高まりが、ヘルスケア施設全体での胆道ステントの採用を促進し、市場規模を拡大しています。Verified Market Researchのアナリストによると、胆道ステント市場は、2024年には3億4,219万米ドルの評価を下回り、予測期間中に4億9,036万米ドルの評価に達すると推定されます。

胆道ステント市場の急拡大は、主にステント技術の進歩が進み、患者の転帰が改善され、合併症が減少したことによります。材料と設計の継続的な技術革新は、市場のCAGRに影響を与える重要な要因として認識されています。これにより、市場は2026年から2032年にかけてCAGR 4.60%で成長します。

胆道ステント市場定義/概要

胆道ステントは、一般に腫瘍、胆石、狭窄などの疾患によって引き起こされる胆管の閉塞を治療するために使用される医療機器です。これらのステントは胆管に挿入され、肝臓から腸への胆汁の適切な流れを確保し、感染やその他の合併症のリスクを低減します。胆道ステントの製造にはプラスチックや金属を含む様々な素材が使用され、患者固有のニーズや閉塞の重症度に基づいてそれぞれのタイプが選択されます。胆道ステントの留置には一般的に低侵襲手術が用いられ、回復時間の短縮と患者の不快感の軽減に貢献しています。

胆管炎や胆道閉鎖症などの胆道疾患の有病率の増加が、ヘルスケア環境全体におけるこれらのステントの採用増加の原動力となっています。さらに、薬剤溶出ステントや生分解性オプションなどのステント技術の進歩も、胆道ステント需要の増加に寄与する主な要因と見られています。こうした動向は市場の成長を促進し、世界中の患者にとっての治療へのアクセス性と有効性を高めると期待されています。

技術的進歩は胆道ステント市場の成長に影響を与えているか？

技術の進歩は、胆道ステント市場の成長における主要な促進要因として認識されています。完全被覆自己拡張型金属ステント（FCSEMS）や生体吸収性ステントの開発など、ステントの設計や材料における技術革新は、患者の予後を改善し合併症を最小限に抑えるために統合されています。

これらの進歩は、手技の成功率を高め、再手術の必要性を減少させたと評価されており、ヘルスケアプロバイダーによる採用の拡大を促しています。さらに、医療従事者が胆道閉塞に対するより効率的で効果的な解決策を求めているため、低侵襲技術の導入がこれらの機器の世界の普及を拡大する一因として促進されています。

胆道ステント市場の成長に影響を与える主な抑制要因は？

胆道ステント市場の成長は、ステント留置手技に関連する高額な費用と、専門的な医療従事者の利用可能性が限られていることが制約となっています。先進的な胆道ステント留置技術へのアクセスは、特に新興国市場では法外なコストのためにいくつかの地域で制限されています。

さらに、胆道ステントの普及を制限する要因として、ステントの移動、感染、その他の合併症のリスクが指摘されています。こうした市場抑制要因は、手技を実施するために熟練した専門医が必要であることがさらに追い打ちをかけ、特にヘルスケア・インフラが限られている地域では、市場成長に影響を与えている要因となっています。

目次

第1章 世界の胆道ステント市場の導入

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 胆道ステントの世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 胆道ステントの世界市場、製品別

• 概要
• 胆道用金属ステント
• 胆道プラスチックステント

第6章 胆道ステントの世界市場：エンドユーザー別

• 概要
• 病院
• 外来手術センター

第7章 胆道ステントの世界市場：用途別

• 概要
• 胆膵漏出
• 膵がん
• 良性胆道狭窄
• 胆石

第8章 胆道ステントの世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 世界の胆道ステント市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• Allium Medical Solutions
• Boston Scientific Corporation
• Conmed Corporation
• Cook Medical LLC
• Dispomedica GmbH
• ELLA-CS
• s.r.o
• ENDO-FLEX GmbH
• Gadelius Medical K.K.
• I Tech Co., Ltd.
• Medi-Globe GmbH
• Medi-Globe Technologies GmbH
• Medtronic plc
• Merit Medical Systems, Inc.
• Micro-Tech（Nanjing）Co., Ltd.
• Olympus Corporation
• Optimed Medizinische Instrumente GmbH
• Bard（acquired by BD）
• Taewoong Medical Co., Ltd.
• Xlumena, Inc.（acquired by Boston Scientific）

第11章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Biliary Stents Market Valuation - 2026-2032

Rising incidences of biliary diseases, such as biliary strictures and gallstones, have significantly increased the demand for minimally invasive procedures. The growing preference for these treatments has driven the adoption of biliary stents across healthcare facilities, expanding the market size. According to the analyst from Verified Market Research, the Biliary Stents Market is estimated to reach a valuation of USD 490.36 Million over the forecast subjugating around USD 342.19 Million valued in 2024.

The rapid expansion of the biliary stents market is primarily driven by increasing advancements in stent technologies, leading to improved patient outcomes and reduced complications. The ongoing innovation in materials and design has been recognized as a key factor influencing the market's CAGR. It enables the market to grow at a CAGR of 4.60% from 2026 to 2032.

Biliary Stents Market: Definition/ Overview

Biliary stents are medical devices used to treat obstructions in the bile ducts, commonly caused by conditions such as tumors, gallstones, or strictures. These stents are inserted into the bile ducts to ensure proper bile flow from the liver to the intestine, reducing the risk of infection and other complications. Various materials, including plastic and metal, are employed in the production of biliary stents, with each type selected based on patient-specific needs and the severity of the obstruction. Minimally invasive procedures are typically used for the placement of biliary stents, contributing to faster recovery times and reduced patient discomfort.

The growing prevalence of biliary disorders, such as cholangitis and biliary atresia, has driven the increasing adoption of these stents across healthcare settings. Additionally, advancements in stent technology, including drug-eluting stents and biodegradable options, have been viewed as key factors contributing to the rising demand for biliary stents. These trends are expected to fuel market growth and enhance the accessibility and effectiveness of treatments for patients worldwide.

we are Technological Advancements Influencing the Growth of the iliary Stents Market?

Technological advancements have been recognized as a key driver in the growth of the biliary stents market. Innovations in stent design and materials, such as the development of fully covered self-expanding metal stents (FCSEMS) and bioabsorbable stents, are being integrated to enhance patient outcomes and minimize complications.

These advancements have been credited with increasing procedural success rates and reducing the need for repeat interventions, which has encouraged greater adoption by healthcare providers. Additionally, the implementation of minimally invasive techniques has been promoted as a contributing factor in expanding the global reach of these devices, as healthcare professionals seek more efficient and effective solutions for biliary obstructions.

What are the Major Restraints Affecting the Growth of the Biliary Stents Market?

The growth of the biliary stents market has been constrained by the high costs associated with stent placement procedures and the limited availability of specialized medical professionals. Access to advanced biliary stenting technology has been restricted in several regions due to the prohibitive costs, particularly in developing markets.

Furthermore, risks of stent migration, infection, and other complications have been noted as factors that may limit the widespread adoption of biliary stents. These restraints are further compounded by the requirement for skilled specialists to perform the procedures, a factor that has impacted the market growth, particularly in areas with limited healthcare infrastructure.

Category-Wise Acumens

What Factors Contribute to the Dominance of Hospitals as the Leading End-User Segment in the Biliary Stents Market?

According to VMR Analyst, the dominance of hospitals in the biliary stents market has been driven by several factors, including the availability of advanced medical infrastructure and the presence of skilled healthcare professionals. Hospitals are equipped with state-of-the-art imaging and surgical tools that allow for precise stent placement, particularly in complex cases such as biliopancreatic leakages and pancreatic cancer.

Moreover, the capacity to manage post-operative care and monitor patients for potential complications, such as stent migration or infections, has positioned hospitals as the preferred setting for biliary stent procedures. The higher patient inflow for major surgical interventions has also been seen as a factor consolidating the leadership of hospitals in this market segment.

What are the Potential Factors Driving the Growth of Biliary Metal Stents over Plastic Stents in the Market?

According to VMR Analyst, the growing preference for biliary metal stents over plastic stents has been attributed to their longer patency rates and reduced need for frequent replacements. Metal stents, particularly self-expanding metal stents (SEMS), have been found to be more durable and resistant to occlusion, making them more suitable for chronic conditions like pancreatic cancer and benign biliary strictures.

Additionally, the capability of metal stents to maintain lumen patency for extended periods has been highlighted as a key advantage in reducing hospital readmissions and intervention costs. Although plastic stents remain a cost-effective solution for temporary conditions, metal stents are being increasingly adopted due to their enhanced performance and longevity in managing long-term biliary obstructions.

Country/Region-wise Acumens

What are the Key Factors Contributing to North America's Dominance in the Biliary Stents Market?

According to VMR Analyst, North America's dominance in the biliary stents market has been primarily attributed to the region's advanced healthcare infrastructure and the high prevalence of biliary diseases, such as pancreatic cancer and gallstones. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), approximately 10-15% of adults in the United States have gallstones, representing about 25 million people.

Increased adoption of innovative stenting technologies, coupled with significant healthcare expenditure, has further strengthened the region's market position. The presence of leading medical device manufacturers and well-established reimbursement policies has facilitated access to cutting-edge biliary stent solutions. Additionally, the rising geriatric population, which is more susceptible to biliary conditions, has been recognized as a significant factor driving market growth in North America.

How is the Rapidly Growing Healthcare Sector in the Asia Pacific Influencing the Biliary Stents Market?

According to VMR Analyst, the rapidly expanding healthcare sector in the Asia Pacific has significantly influenced the growth of the biliary stents market in the region. Increasing investments in healthcare infrastructure, along with the rising prevalence of biliary disorders, have been noted as key factors driving market demand.

The Asia Pacific region is experiencing a rapid demographic shift toward an aging population, which is associated with a higher risk of biliary diseases. According to the United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), the number of people aged 65 and above in the region is projected to increase from 612 million in 2022 to approximately 1.3 billion by 2050.

Countries such as China, India, and Japan have seen growing adoption of minimally invasive procedures, supported by favorable government initiatives and improved access to healthcare. Additionally, the rising awareness about advanced biliary treatments and the increasing affordability of stent procedures have contributed to the robust growth of the biliary stents market in the Asia Pacific.

Competitive Landscape

The Biliary Stents Market's competitive landscape is characterized by a varied range of companies, including technology developers, plant operators, and service providers, all striving for market share in an increasingly dynamic and growing industry.

Some of the prominent players operating in the biliary stents market include:

Allium Medical Solutions Ltd.

Boston Scientific Corporation

Conmed Corporation

Cook Medical LLC

Dispomedica GmbH

ELLA-CS, s.r.o.

ENDO-FLEX GmbH

ETERMED

Gadelius Medical K.K.

I. Tech Co., Ltd.

Medi-Globe GmbH

Medi-Globe Technologies GmbH

Medtronic plc

Merit Medical Systems, Inc.

Micro-Tech (Nanjing) Co., Ltd.

Olympus Corporation

Optimed Medizinische Instrumente GmbH

Bard (acquired by BD)

Taewoong Medical Co., Ltd.

Xlumena, Inc. (acquired by Boston Scientific)

Latest Developments

In February 2023, Olympus Corporation announced the acquisition of Taewoong Medical, a South Korean manufacturer of gastrointestinal (including biliary tract) metallic stents. Taewoong will receive $370 million in cash under the agreement, with $255.5 million paid at closing and the remaining $114.5 million paid based on future milestones. In May 2021, amg International GmbH, a wholly owned subsidiary of Dublin, Ireland-based Q3 Medical Devices Limited (Q3), strengthens its position as a leader in the rapid development of novel biodegradable implants. The Company announced that its second fully biodegradable product, the UNITY-B balloon expandable biodegradable biliary stent (BEBS) for endoscopic use, has received CE Mark approval. The UNITY-B will be used in conjunction with the ARCHIMEDESTM, the world's first CE-approved pancreaticobiliary biodegradable implant.

Biliary Stents Market, By Category

• Product
• Biliary Metal Stents
• Biliary Plastic Stents
• End-User
• Hospitals
• Ambulatory Surgical Centers
• Application
• Bilio-pancreatic Leakages
• Pancreatic Cancer
• Benign Biliary Strictures
• Gallstones
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL BILIARY STENTS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL BILIARY STENTS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL BILIARY STENTS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Biliary Metal Stents
• 5.3 Biliary Plastic Stent

6 GLOBAL BILIARY STENTS MARKET, BY END-USER

• 6.1 Overview
• 6.2 Hospitals
• 6.3 Ambulatory Surgical Centers

7 GLOBAL BILIARY STENTS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Bilio-pancreatic Leakages
• 7.3 Pancreatic Cancer
• 7.4 Benign Biliary Strictures
• 7.5 Gallstones

8 GLOBAL BILIARY STENTS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL BILIARY STENTS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Allium Medical Solutions
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Boston Scientific Corporation
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Conmed Corporation
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Cook Medical LLC
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Dispomedica GmbH
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 ELLA-CS
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 s.r.o
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 ENDO-FLEX GmbH
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Gadelius Medical K.K.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 I Tech Co., Ltd.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments
• 10.11 Medi-Globe GmbH
  • 10.11.1 Overview
  • 10.11.2 Financial Performance
  • 10.11.3 Product Outlook
  • 10.11.4 Key Developments
• 10.12 Medi-Globe Technologies GmbH
  • 10.12.1 Overview
  • 10.12.2 Financial Performance
  • 10.12.3 Product Outlook
  • 10.12.4 Key Developments
• 10.13 Medtronic plc
  • 10.13.1 Overview
  • 10.13.2 Financial Performance
  • 10.13.3 Product Outlook
  • 10.13.4 Key Developments
• 10.14 Merit Medical Systems, Inc.
  • 10.14.1 Overview
  • 10.14.2 Financial Performance
  • 10.14.3 Product Outlook
  • 10.14.4 Key Developments
• 10.15 Micro-Tech (Nanjing) Co., Ltd.
  • 10.15.1 Overview
  • 10.15.2 Financial Performance
  • 10.15.3 Product Outlook
  • 10.15.4 Key Developments
• 10.16 Olympus Corporation
  • 10.16.1 Overview
  • 10.16.2 Financial Performance
  • 10.16.3 Product Outlook
  • 10.16.4 Key Developments
• 10.17 Optimed Medizinische Instrumente GmbH
  • 10.17.1 Overview
  • 10.17.2 Financial Performance
  • 10.17.3 Product Outlook
  • 10.17.4 Key Developments
• 10.18 Bard (acquired by BD)
  • 10.18.1 Overview
  • 10.18.2 Financial Performance
  • 10.18.3 Product Outlook
  • 10.18.4 Key Developments
• 10.19 Taewoong Medical Co., Ltd.
  • 10.19.1 Overview
  • 10.19.2 Financial Performance
  • 10.19.3 Product Outlook
  • 10.19.4 Key Developments
• 10.20 Xlumena, Inc. (acquired by Boston Scientific)
  • 10.20.1 Overview
  • 10.20.2 Financial Performance
  • 10.20.3 Product Outlook
  • 10.20.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research